On May, 8 Veru Inc. (VERU) EPS Estimated At $-0.02

April 17, 2018 - By Elizabeth Jones

Investors expect Veru Inc. (NASDAQ:VERU)’s quarterly earnings on May, 8., according to RTT. Last year’s earnings per share was $-0.06, while now analysts expect change of 66.67 % up from current $-0.02 earnings per share. -33.33 % EPS growth is what analysts predict. $-0.03 earnings per share was reported for last [previous quarter]. The stock decreased 2.21% or $0.04 during the last trading session, reaching $1.77.Currently Veru Inc. is uptrending after 64.49% change in last April 17, 2017. VERU has also 48,423 shares volume. The stock outperformed the S&P 500 by 52.94%.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products.The firm is worth $94.72 million. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever.Last it reported negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

Veru Inc. (NASDAQ:VERU) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.